Advancing Therapies for Neurofibromatosis Type 1 (NF1): Lessons Learned from Every Patient
Brigitte Widemann, M.D.
Chief, Pediatric Oncology Branch
Head, Pharmacology and Experimental Therapeutics Section
CCR Deputy Director
National Institutes of Health, National Cancer Institute
Dr. Brigitte Widemann is a pediatric oncologist with the primary interest of developing effective therapies for children and adults with genetic tumor predisposition syndromes, such as neurofibromatosis type 1 (NF1), and rare solid tumors through innovative clinical trial design. Dr. Widemann currently serves as the head of the Pharmacology & Experimental Therapeutics Section and as Chief of NCI’s Pediatric Oncology Branch. Anticancer drug discovery and development are moving towards a more rational and targeted approach. The application of new molecularly targeted agents to the treatment of childhood cancers and neurofibromatosis type 1 (NF1) is a research objective of the Pharmacology & Experimental Therapeutics Section (PETS). In addition to studying the pharmacology, pharmacokinetics, pharmacodynamics, and toxicities of these novel agents, it is also a goal of the PETS to evaluate novel clinical trial designs and trial endpoints, which may be more applicable for molecularly targeted agents.
This page was last updated on Thursday, November 18, 2021